NASDAQ: IMNN
Imunon, Inc.CIK 0000749647 · SIC 2834 · Pharmaceutical Preparations
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (TCBI 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade IMNN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 11, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 1,464,655 | 1,226,954 | 3,801,963 | 3,392,046 |
| General and administrative | 1,326,891 | 1,540,910 | 3,296,135 | 3,521,117 |
| Total operating expenses | 2,791,546 | 2,767,864 | 7,098,098 | 6,913,163 |
| Loss from operations | (2,791,546) | (2,767,864) | (7,098,098) | (6,913,163) |
| Other income (expense): | ||||
| Investment income, net | 32,518 | 27,305 | 90,048 | 70,109 |
| Interest expense | (77,273) | - | (77,273) | - |
| Change in fair value of derivative liability | 22,187 | - | 22,187 | - |
| Total other income (expense), net | (22,568) | 27,305 | 34,962 | 70,109 |
| Net loss | (2,814,114) | (2,740,559) | (7,063,136) | (6,843,054) |
| Deemed Dividend Series A Preferred Stock | (18,052) | - | (18,052) | - |
| Net loss available to common share available to common shareholders | (2,832,166) | (2,740,559) | (7,081,188) | (6,843,054) |
| Net loss per common share available to common shareholders | ||||
| Basic and diluted | (0.54) | (2.15) | (1.38) | (6.08) |
| Weighted average shares outstanding | ||||
| Basic and diluted | 5,232,625 | 1,277,217 | 5,134,039 | 1,124,730 |
Condensed Consolidated Balance Sheets
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | 6,864,378 | 8,781,059 |
| Advances and deposits on clinical programs and other current assets | 1,826,825 | 1,942,685 |
| Total current assets | 8,691,203 | 10,723,744 |
| Property and equipment (at cost, less accumulated depreciation and amortization) | 459,016 | 529,936 |
| Other assets: | ||
| Restricted cash | 5,000,000 | – |
| Operating lease right-of-use assets, net | 788,894 | 984,436 |
| Deposits and other assets | 50,000 | 50,000 |
| Total other assets | 5,838,894 | 1,034,436 |
| Total assets | 14,989,113 | 12,288,116 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable trade | 1,618,497 | 1,392,829 |
| Other accrued liabilities | 1,228,568 | 2,824,646 |
| Note payable Note A – current portion | 1,500,000 | – |
| Operating lease liability current portion | 431,781 | 406,354 |
| Total current liabilities | 4,778,846 | 4,623,829 |
| Note payable Note A | 673,271 | – |
| Note payable Note B | 4,860,831 | – |
| Operating lease liability non-current portion | 379,409 | 602,411 |
| Derivative liability associated with redemption feature of Note A | 107,969 | – |
| Total liabilities | 10,800,326 | 5,226,240 |
| Commitments and contingencies | - | – |
| Stockholders’ equity: | ||
| Preferred stock $0.01 par value (100,000 shares authorized; 250 shares issued and outstanding at June 30, 2026, and no shares issued or outstanding at December 31, 2025) | 3 | – |
| Additional paid-in capital preferred stock | 2,251,918 | – |
| Common stock $0.01 par value (350,000,000 shares authorized; 4,665,662 and 3,419,652 shares issued at June 30, 2026 and December 31, 2025, respectively; and 4,665,660 and 3,419,650 shares outstanding at June 30, 2026 and December 31, 2025, respectively) | 46,657 | 34,197 |
| Additional paid-in capital | 430,336,605 | 428,410,939 |
| Accumulated deficit | (428,361,208) | (421,298,072) |
| Total stockholders’ equity before treasury stock | 4,273,975 | 7,147,064 |
| Treasury stock, at cost (2 shares at June 30, 2026 and December 31, 2025) | (85,188) | (85,188) |
| Total stockholders’ equity | 4,188,787 | 7,061,876 |
| Total liabilities and stockholders’ equity | 14,989,113 | 12,288,116 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (7,063,136) | (6,843,054) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 140,000 | 141,690 |
| Amortization of right-of-use assets | 195,542 | 220,911 |
| Stock-based compensation | 641,871 | 327,174 |
| Common stock issued in exchange for compensation and services | 455,351 | - |
| Change in fair value of derivative liability | (22,187) | - |
| PIK interest accretion A-1 Note | 16,096 | - |
| Ammortization of debt discount and issuance costs | 35,410 | - |
| Ammortization of debt issuance costs B-Note | 6,983 | - |
| Net changes in: | ||
| Advances, deposits, and other current assets | 115,860 | (26,277) |
| Accounts payable and accrued liabilities | (1,532,422) | 381,116 |
| Net cash used in operating activities | (7,010,632) | (5,798,440) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (69,080) | (276,983) |
| Net cash used in investing activities | (69,080) | (276,983) |
| Cash flows from financing activities: | ||
| Proceeds from sale of common stock, net of issuance costs | 842,704 | 2,963,738 |
| Proceeds from sale of preferred stock, net of issuance costs | 2,288,025 | |
| Proceeds from issuance of notes payable, net of issuance costs | 7,034,102 | |
| Exercise of pre-funded warrants, net | (1,800) | - |
| Proceeds from issuance of common stock upon exercise of warrants | - | 1,967,694 |
| Net cash (used in) provided by financing activities | 10,163,031 | 4,931,432 |
| Net change in cash, cash equivalents and restricted cash | 3,083,319 | (1,143,991) |
| Cash, cash equivalents and restricted cash at beginning of period | 8,781,059 | 5,872,767 |
| Cash , cash equivalents and restricted cash at end of period | 11,864,378 | 4,728,776 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗